|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0245 - 0.0398|
|52 Week Range||0.0200 - 0.4900|
|Beta (5Y Monthly)||2.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Company is delighted to announce the launching of its premium CBD product lines in the coming weeks. The launch includes the CBD cosmetics line and the CBD coffee line in pharmacies, convenience stores and hotels across South Africa.
Barcelona, Spain, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), is positioning itself to become a major player in the US$166B medical CBD (cannabidiol) space, as well as the promising psilocybin and medicinal mushroom health sector. The company is pleased to announce that Dr. Hyder A. Khoja (“Dr. Khoja”) is joining Wuhan General Group as Chief Scientific Officer. In his role as CSO, Dr. Khoja will oversee the company’s core research and product development to commercialization.
"Throughout his tenure as CEO, Mr. Kamaneh was instrumental in leading Wuhan in surpassing many milestones, and he has provided sound financial leadership to the Company," said Jeffrey Robinson, newly appointed CEO. Mr. Kamaneh’s transition as Chief Financial Officer within the company only strengthens managements with his more than fifteen years of experience in finance and various manufacturing industries. Ramy brings a rare combination of expertise leading both public companies and private companies through significant stages of growth.
The company would like to clarify for all past, current and potential future shareholders that Wuhan General Group is a US-registered corporation and has no dealings with any Chinese parties as it relates to its ongoing business activities. To remove any possible confusion with its current name and to better reflect the nature of the business, the Company has retained the services of a law firm to specifically take all necessary steps to file a name change with FINRA. Once approved, the company will issue a press release to inform shareholders.
Wuhan General Group , Inc. , is pleased to announce the closing of our previously announced Letter of Intent to acquire 49% of Biodelta Nutraceuticals, Ltd. assets which includes the land, the buildings, and the infrastructure as well as the specialized greenhouse and drying ovens.
BARCELONA, Spain, May 17, 2019 -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC: WUHN) (the "Company" and "Wuhan"), is thrilled to announce the signing of a very.
BARCELONA, Spain, May 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), and M2BIO is delighted to share the voting results of Initiative 301 held in Denver last night. "This is a big step forward for medicine and research into medicinal mushrooms.
BARCELONA, Spain, April 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has created a new division dedicated to exploring opportunities in the psychedelic medicine space. The new division, M2BIO will be headed up by Wuhan's CMO, Dr. Anna Morera Lorelta. Researchers are having great success in treating depression, post-traumatic stress disorder (PTSD), anxiety and certain addictions with Psilocybin, the active naturally occurring psychedelic pro-drug compound produced by specific mushrooms, known as "magic mushrooms".
BARCELONA, Spain, March 28, 2019 -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC: WUHN) (the "Company" and "Wuhan"), announced today that its subsidiary MJ.
LOS ANGELES, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (WUHN) (the "Company" and "Wuhan"), announced today that its wholly-owned subsidiary MJ MedTech, Inc. (MJ MedTech) and Biodelta Nutraceuticals, Ltd. (Biodelta) have entered into a joint venture to develop, brand, market and commercialize the internationally trademarked Dr. AnnaRx. The joint venture calls for an initial pilot whereby the Dr. AnnaRx line of CBD based products will be sold (as regulations allow) across South Africa in more than 1,000 pharmacies. This partnership marks a very strong start to 2019 for MJ MedTech as the Company expects to have product on the shelves by Q2/3 of 2019.
With the closing of the acquisition, Jeff Robinson will continue in his role as CEO and President of MJ MedTech, and will be joining the Board of Directors of Wuhan. Also, Dr. Anna Leralta will be appointed Secretary and Treasurer of Wuhan, and will be joining the Board of Directors of Wuhan as well.
MONTREAL, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announces today that the Company is successfully gaining a strong foothold in Canada, Europe, US and Australia through Cannabis regulatory compliance, either by obtaining or having access to the needed permits to cultivate, transform and sell cannabis products in the permitted location. This will secure the proper supply chain to provide high quality cannabis products from all around the world that can be purchased at a retail store nearby as well as online. This alliance will also position Wuhan as a leader in curating the knowledge and clinical research to educate our consumers on the products provided and assist them in their purchases.